Építés alatt – nem éles oldal
Belépés
VisszavonvaFázis nélkül

Assessing Superion Clinical Endpoints vs. Decompression

A legfontosabb adatok

Ki végzi
VertiFlex, Incorporated
Hol
Birmingham, Carlsbad, Celebration, Shreveport és Willow Grove (Egyesült Államok)Mind a 5 helyszín megnézése
Azonosító
Állapot
Visszavonva
Kezdés
2017. febr. 8.
Befejezés
2025. júl. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Superion® IDS
  • Direct decompression Surgery
A regiszteradat frissítve
2019. június 12.
Miért állt le
FDA and Sponsor closed trial. New post-marketing approval trial in development.

Ki vehet részt

Életkor
45 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 39 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female subjects ≥ 45 years of age
  • Persistent leg/buttock/groin pain, with or without back pain that is consistently relieved by flexion activities (example: sitting or bending over a shopping cart)
  • Subjects who have been symptomatic and undergoing conservative care treatment for at least 6 months, without relief
  • Diagnosis of degenerative spinal stenosis of the lumbar spine, defined as the narrowing of the midline sagittal spinal canal (central) and/or narrowing between the facet superior articulating process (SAP), the posterior vertebral margin (lateral access), and the nerve root canal (foraminal)
  • Radiographic confirmation of at least moderate spinal stenosis which narrows the central, lateral, or foraminal spinal canal at one or two contiguous levels from L1-L5. Moderate spinal stenosis is defined as ≤50% reduction in lateral/central foramen
  • Must present with moderately impaired Physical Function (PF) defined as a score of ≥ 2.0 of the Zurich Claudication Questionnaire (ZCQ)
  • Subjects who are able to give voluntary, written informed consent to participate in this clinical investigation and from whom consent has been obtained
  • Subjects, who, in the opinion of the Clinical Investigator, are able to understand this clinical investigation, cooperate with the investigational procedures and are willing to return for all the required post-treatment follow-ups; Note: In Criteria #5, all imaging used to confirm LSS should be completed within 4 weeks prior to enrollment. Radiographic confirmation of LSS may include MRI and/or CT

Ki nem vehet részt

  • Diagnosis of lumbar spinal stenosis which, if the patient were randomized to the Superion arm, would not require any direct neural decompression or surgical intervention other than that required to implant the Superion® device or if randomized to the direct decompression arm, would not require a decompression procedure which would create significant instability requiring spinal fusion, with or without instrumentation
  • Lumbar spinal stenosis at more than two levels determined pre-operatively to require surgical intervention
  • Prior surgery of the lumbar spine at the treatment level(s)
  • Currently undergoing immunosuppressive therapy or long-term steroid use
  • Enrolled in the treatment phase of another drug or device clinical investigation (currently within past 30 days)
  • Significant peripheral vascular disease (diminished dorsalis pedis or tibial pulses)
  • Cauda equina syndrome (defined as neural compression causing neurogenic bowel or bladder dysfunction)
  • Active (systemic, or local in disc or spine) infection at time of surgery
  • Active systemic disease such as AIDS, HIV, hepatitis, etc
  • Paget's disease at involved segment or metastasis to the vertebrae, osteomalacia, or other metabolic bone disease
  • Known allergy to titanium or titanium alloys
  • Tumor in the spine or a malignant tumor except for basal cell carcinoma
  • Known or suspected history of alcohol and/or drug abuse
  • Any condition that, in the opinion of the Investigator, would affect the patient's welfare or outcome of the clinical trial
  • Axial back pain only
  • Fixed motor deficit in lower extremity(ies)
  • Unremitting pain in any spinal position
  • Significant peripheral neuropathy or acute denervation secondary to radiculopathy
  • Significant instability of the lumbar spine as defined by ≥ 3mm translation or ≥ 5° angulation through flexion/extension films
  • Sustained pathologic fractures of the vertebrae or multiple fractures of the vertebrae and/or hips
  • Spondylolisthesis or degenerative spondylolisthesis greater than grade 1 (on a scale of 1-4)
  • Spondylosis (pars fracture) at the treatment level(s)
  • Degenerative lumbar scoliosis with a Cobb angle of > 10° at treatment level
  • Osteoporosis, defined as a DEXA bone density measurement T score ≤ -2.5
  • Morbid obesity, defined as Body Mass Index (BMI) >40kg/m2
  • Prisoner or transient
  • Life expectancy less than two years
  • Any significant psychological disturbance, psychotic or neurotic, that could impair the consent process or ability to complete subject self-report questionnaires
  • Involved in pending litigation of the spine or worker's compensation related to the back
  • Congenital defect of the spine
  • Pregnant or lactating

Helyszínek itt: Egyesült Államok

  • Alabama Clinical Therapeutics, LLCBirmingham, Egyesült Államok
  • Coastal Pain Spinal DiagnosticsCarlsbad, Egyesült Államok
  • Lake Nona Medical ArtsCelebration, Egyesült Államok
  • Spine Institute of LouisianaShreveport, Egyesült Államok
  • Rothman InstituteWillow Grove, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

PURPOSE: The primary purpose of this study is to demonstrate that the Composite Clinical Success of the study group receiving the Superion® IDS is not inferior to the success rate observed in the study group treated by direct decompression at 60 months follow-up. Secondarily, the trial is intended to establish that Composite Clinical Success of the study group receiving the Superion® IDS at 24 months is not inferior to the success rate observed at 24 months in patients treated with the Superion® IDS in the original IDE trial. Thirdly, the trial is intended to establish that Composite Clinical Success of the population receiving the Superion® IDS in this trial at 24 months is not inferior to the success rate observed at 24 months in patients treated with direct decompression.

A vizsgálat 2 csoportja

  • Indirect Decompression SystemMár használt kezelés, összehasonlításként

    Superion® IDS surgical procedure

    Kezelés: Superion® IDS

  • Direct decompression SurgeryMár használt kezelés, összehasonlításként

    Open, direct decompression surgical procedure

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A 2 and 5 Year Comparative Evaluation of Clinical Outcomes in the Treatment of Moderate Lumbar Spinal Stenosis With the Superion® Indirect Decompression System (IDS) vs. Direct Decompression Surgery for FDA Actual Conditions of Use Study
A regiszteradat frissítve
2019. június 12.